NCT04701021View on ClinicalTrials.gov

TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

August 16, 2023

Study Completion Date

August 16, 2023

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

TENDU

The vaccine is administrated by subcutaneous injections, one injection per drug substance (four separate injections) consecutively.

Trial Locations (1)

0379

Oslo University Hospital, The Norwegian Radium Hospital, Oslo

All Listed Sponsors
lead

Ultimovacs ASA

INDUSTRY

NCT04701021 - TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy | Biotech Hunter | Biotech Hunter